Report cover image

Global DNA & RNA Oligonucleotides Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 194 Pages
SKU # APRC20361701

Description

Summary

According to APO Research, The global DNA & RNA Oligonucleotides market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for DNA & RNA Oligonucleotides is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of DNA & RNA Oligonucleotides include Berry Genomics, BGI, Brooks Life Sciences, Dna Link, Eurofins Scientific, Genotypic Technology, Illumina, LabCorp and Macrogen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for DNA & RNA Oligonucleotides, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of DNA & RNA Oligonucleotides, also provides the revenue of main regions and countries. Of the upcoming market potential for DNA & RNA Oligonucleotides, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the DNA & RNA Oligonucleotides revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global DNA & RNA Oligonucleotides market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for DNA & RNA Oligonucleotides revenue, projected growth trends, production technology, application and end-user industry.

DNA & RNA Oligonucleotides Segment by Company

Berry Genomics
BGI
Brooks Life Sciences
Dna Link
Eurofins Scientific
Genotypic Technology
Illumina
LabCorp
Macrogen
Natera
Roche
DNA & RNA Oligonucleotides Segment by Type

DNA Oligonucleotides
RNA Oligonucleotides
DNA & RNA Oligonucleotides Segment by Application

Biopharma Companies
Academic & Research Organizations
Hospitals and Clinics
Others
DNA & RNA Oligonucleotides Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA & RNA Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DNA & RNA Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA & RNA Oligonucleotides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of DNA & RNA Oligonucleotides in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of DNA & RNA Oligonucleotides company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, DNA & RNA Oligonucleotides revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 DNA & RNA Oligonucleotides Market by Type
1.2.1 Global DNA & RNA Oligonucleotides Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 DNA Oligonucleotides
1.2.3 RNA Oligonucleotides
1.3 DNA & RNA Oligonucleotides Market by Application
1.3.1 Global DNA & RNA Oligonucleotides Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Biopharma Companies
1.3.3 Academic & Research Organizations
1.3.4 Hospitals and Clinics
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 DNA & RNA Oligonucleotides Market Dynamics
2.1 DNA & RNA Oligonucleotides Industry Trends
2.2 DNA & RNA Oligonucleotides Industry Drivers
2.3 DNA & RNA Oligonucleotides Industry Opportunities and Challenges
2.4 DNA & RNA Oligonucleotides Industry Restraints
3 Global Growth Perspective
3.1 Global DNA & RNA Oligonucleotides Market Perspective (2020-2031)
3.2 Global DNA & RNA Oligonucleotides Growth Trends by Region
3.2.1 Global DNA & RNA Oligonucleotides Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global DNA & RNA Oligonucleotides Market Size by Region (2020-2025)
3.2.3 Global DNA & RNA Oligonucleotides Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global DNA & RNA Oligonucleotides Revenue by Players
4.1.1 Global DNA & RNA Oligonucleotides Revenue by Players (2020-2025)
4.1.2 Global DNA & RNA Oligonucleotides Revenue Market Share by Players (2020-2025)
4.1.3 Global DNA & RNA Oligonucleotides Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global DNA & RNA Oligonucleotides Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global DNA & RNA Oligonucleotides Key Players Headquarters & Area Served
4.4 Global DNA & RNA Oligonucleotides Players, Product Type & Application
4.5 Global DNA & RNA Oligonucleotides Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global DNA & RNA Oligonucleotides Market CR5 and HHI
4.6.3 2024 DNA & RNA Oligonucleotides Tier 1, Tier 2, and Tier 3
5 DNA & RNA Oligonucleotides Market Size by Type
5.1 Global DNA & RNA Oligonucleotides Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
5.3 Global DNA & RNA Oligonucleotides Revenue Market Share by Type (2020-2031)
6 DNA & RNA Oligonucleotides Market Size by Application
6.1 Global DNA & RNA Oligonucleotides Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
6.3 Global DNA & RNA Oligonucleotides Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Berry Genomics
7.1.1 Berry Genomics Comapny Information
7.1.2 Berry Genomics Business Overview
7.1.3 Berry Genomics DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.1.4 Berry Genomics DNA & RNA Oligonucleotides Product Portfolio
7.1.5 Berry Genomics Recent Developments
7.2 BGI
7.2.1 BGI Comapny Information
7.2.2 BGI Business Overview
7.2.3 BGI DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.2.4 BGI DNA & RNA Oligonucleotides Product Portfolio
7.2.5 BGI Recent Developments
7.3 Brooks Life Sciences
7.3.1 Brooks Life Sciences Comapny Information
7.3.2 Brooks Life Sciences Business Overview
7.3.3 Brooks Life Sciences DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.3.4 Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio
7.3.5 Brooks Life Sciences Recent Developments
7.4 Dna Link
7.4.1 Dna Link Comapny Information
7.4.2 Dna Link Business Overview
7.4.3 Dna Link DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.4.4 Dna Link DNA & RNA Oligonucleotides Product Portfolio
7.4.5 Dna Link Recent Developments
7.5 Eurofins Scientific
7.5.1 Eurofins Scientific Comapny Information
7.5.2 Eurofins Scientific Business Overview
7.5.3 Eurofins Scientific DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.5.4 Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio
7.5.5 Eurofins Scientific Recent Developments
7.6 Genotypic Technology
7.6.1 Genotypic Technology Comapny Information
7.6.2 Genotypic Technology Business Overview
7.6.3 Genotypic Technology DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.6.4 Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio
7.6.5 Genotypic Technology Recent Developments
7.7 Illumina
7.7.1 Illumina Comapny Information
7.7.2 Illumina Business Overview
7.7.3 Illumina DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.7.4 Illumina DNA & RNA Oligonucleotides Product Portfolio
7.7.5 Illumina Recent Developments
7.8 LabCorp
7.8.1 LabCorp Comapny Information
7.8.2 LabCorp Business Overview
7.8.3 LabCorp DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.8.4 LabCorp DNA & RNA Oligonucleotides Product Portfolio
7.8.5 LabCorp Recent Developments
7.9 Macrogen
7.9.1 Macrogen Comapny Information
7.9.2 Macrogen Business Overview
7.9.3 Macrogen DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.9.4 Macrogen DNA & RNA Oligonucleotides Product Portfolio
7.9.5 Macrogen Recent Developments
7.10 Natera
7.10.1 Natera Comapny Information
7.10.2 Natera Business Overview
7.10.3 Natera DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.10.4 Natera DNA & RNA Oligonucleotides Product Portfolio
7.10.5 Natera Recent Developments
7.11 Roche
7.11.1 Roche Comapny Information
7.11.2 Roche Business Overview
7.11.3 Roche DNA & RNA Oligonucleotides Revenue and Gross Margin (2020-2025)
7.11.4 Roche DNA & RNA Oligonucleotides Product Portfolio
7.11.5 Roche Recent Developments
8 North America
8.1 North America DNA & RNA Oligonucleotides Revenue (2020-2031)
8.2 North America DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
8.2.1 North America DNA & RNA Oligonucleotides Revenue by Type (2020-2025)
8.2.2 North America DNA & RNA Oligonucleotides Revenue by Type (2026-2031)
8.3 North America DNA & RNA Oligonucleotides Revenue Share by Type (2020-2031)
8.4 North America DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
8.4.1 North America DNA & RNA Oligonucleotides Revenue by Application (2020-2025)
8.4.2 North America DNA & RNA Oligonucleotides Revenue by Application (2026-2031)
8.5 North America DNA & RNA Oligonucleotides Revenue Share by Application (2020-2031)
8.6 North America DNA & RNA Oligonucleotides Revenue by Country
8.6.1 North America DNA & RNA Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America DNA & RNA Oligonucleotides Revenue by Country (2020-2025)
8.6.3 North America DNA & RNA Oligonucleotides Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe DNA & RNA Oligonucleotides Revenue (2020-2031)
9.2 Europe DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
9.2.1 Europe DNA & RNA Oligonucleotides Revenue by Type (2020-2025)
9.2.2 Europe DNA & RNA Oligonucleotides Revenue by Type (2026-2031)
9.3 Europe DNA & RNA Oligonucleotides Revenue Share by Type (2020-2031)
9.4 Europe DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
9.4.1 Europe DNA & RNA Oligonucleotides Revenue by Application (2020-2025)
9.4.2 Europe DNA & RNA Oligonucleotides Revenue by Application (2026-2031)
9.5 Europe DNA & RNA Oligonucleotides Revenue Share by Application (2020-2031)
9.6 Europe DNA & RNA Oligonucleotides Revenue by Country
9.6.1 Europe DNA & RNA Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe DNA & RNA Oligonucleotides Revenue by Country (2020-2025)
9.6.3 Europe DNA & RNA Oligonucleotides Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China DNA & RNA Oligonucleotides Revenue (2020-2031)
10.2 China DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
10.2.1 China DNA & RNA Oligonucleotides Revenue by Type (2020-2025)
10.2.2 China DNA & RNA Oligonucleotides Revenue by Type (2026-2031)
10.3 China DNA & RNA Oligonucleotides Revenue Share by Type (2020-2031)
10.4 China DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
10.4.1 China DNA & RNA Oligonucleotides Revenue by Application (2020-2025)
10.4.2 China DNA & RNA Oligonucleotides Revenue by Application (2026-2031)
10.5 China DNA & RNA Oligonucleotides Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia DNA & RNA Oligonucleotides Revenue (2020-2031)
11.2 Asia DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
11.2.1 Asia DNA & RNA Oligonucleotides Revenue by Type (2020-2025)
11.2.2 Asia DNA & RNA Oligonucleotides Revenue by Type (2026-2031)
11.3 Asia DNA & RNA Oligonucleotides Revenue Share by Type (2020-2031)
11.4 Asia DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
11.4.1 Asia DNA & RNA Oligonucleotides Revenue by Application (2020-2025)
11.4.2 Asia DNA & RNA Oligonucleotides Revenue by Application (2026-2031)
11.5 Asia DNA & RNA Oligonucleotides Revenue Share by Application (2020-2031)
11.6 Asia DNA & RNA Oligonucleotides Revenue by Country
11.6.1 Asia DNA & RNA Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia DNA & RNA Oligonucleotides Revenue by Country (2020-2025)
11.6.3 Asia DNA & RNA Oligonucleotides Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA DNA & RNA Oligonucleotides Revenue (2020-2031)
12.2 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2020-2031)
12.2.1 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2020-2025)
12.2.2 SAMEA DNA & RNA Oligonucleotides Revenue by Type (2026-2031)
12.3 SAMEA DNA & RNA Oligonucleotides Revenue Share by Type (2020-2031)
12.4 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2020-2031)
12.4.1 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2020-2025)
12.4.2 SAMEA DNA & RNA Oligonucleotides Revenue by Application (2026-2031)
12.5 SAMEA DNA & RNA Oligonucleotides Revenue Share by Application (2020-2031)
12.6 SAMEA DNA & RNA Oligonucleotides Revenue by Country
12.6.1 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2020-2025)
12.6.3 SAMEA DNA & RNA Oligonucleotides Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.